EU cross-border health product prescribing: device industry views sought
This article was originally published in Clinica
Medtech companies are among those who have been invited to respond to a consultation on EU cross-border prescribing plans intended to help avoid confusion when healthcare products, including medical devices, are prescribed in one country and dispensed in another.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.